Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Elicera Therapeutics AB (publ) ("Elicera" or the "Company") has prepared an EU growth prospectus (the "Prospectus") for the forthcoming issue of units consisting of shares and warrants with preferential rights for existing shareholders (the "Rights Issue"), which the board of directors resolved on January 18, 2024 and was approved at the extraordinary general meeting on February 20, 2024. The Prospectus was approved by the Swedish Financial Supervisory Authority today February 21, 2024.
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, February 21, 2024, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, will be available on the Company's website, www.elicera.com, on Mangold Fondkommission AB's website, www.mangold.se, and on the Swedish Financial Supervisory Authority's website, www.fi.se. Information about the Rights Issue will be made available on the Company's website and on Mangold Fondkommission AB's website in connection with the beginning of the subscription period.
"Elicera Therapeutics has several value-creating projects for patients affected by severe forms of cancer. Our patented genetic engineering method iTANK makes it possible to develop revolutionary CAR T-cell treatments against solid tumors, something that has not been possible before. To continue the development of our breakthrough therapies, we are now conducting a rights issue that will primarily fund the clinical trial of our most advanced CAR T-cell therapy ELC-301 against B-cell lymphoma.
By carrying out the issue already now, we ensure that the company continues to have a strong financial position during the implementation of our phase I/IIa study with ELC-301. The subscription and guarantee commitments ensure that the study can be carried out with good quality, that we can continue the work with commercialization of the iTANK platform and that we can continue the development of our other drug candidates.
I would like to extend a big thank you to all existing shareholders for your support and trust, which means that we can now take the next step in the development of Elicera."
- Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)
Preliminary timetable for the Rights Issue- February 21, 2024: Record date for obtaining unit rights. Shareholders who are registered in the share register kept by Euroclear Sweden AB on this day receive unit rights for participation in the Rights Issue.
- February 23 - March 5, 2024: Trading with unit rights on Nasdaq First North
- February 23 - March 8, 2024: Subscription period for the Rights Issue
- February 23 - week 12, 2024: Trading with BTU on Nasdaq First North
- March 12, 2024: Estimated date for publication of issue results